XML 23 R14.htm IDEA: XBRL DOCUMENT
v3.22.4

Fair Value Measurements | 9 Months Ended
--- | ---
Dec. 31, 2022
Fair Value Disclosures [Abstract] |
Fair Value Measurements | Fair Value Measurements Fair Value Measurements The Company considers fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company utilizes the following three-level fair value hierarchy to establish the priorities of the inputs used to measure fair value: •Level 1 — Quoted prices in active markets for identical assets or liabilities. •Level 2 — Observable inputs other than quoted market prices included in Level 1, such as: quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. •Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis, excluding assets related to the Company’s defined benefit pension plans, classified by the level within the fair value hierarchy (in thousands):
|  | December 31, 2022 |  | March 31, 2022
|  | Level 1 |  | Level 2 |  | Level 3 |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents |  | $ | 603,163 |  |  | $ | — |  |  | $ | — |  |  | $ | 762,055 |  |  | $ | — |  |  | $ | — |
Investments for deferred compensation plan included in other assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 10 |  |  | $ | — |  |  | $ | — |  |  | $ | 108 |  |  | $ | — |  |  | $ | — |
Common stock |  | 705 |  |  | — |  |  | — |  |  | 2,329 |  |  | — |  |  | — |
Money market funds |  | 9,728 |  |  | — |  |  | — |  |  | 6,765 |  |  | — |  |  | — |
Mutual funds |  | 17,222 |  |  | — |  |  | — |  |  | 19,229 |  |  | — |  |  | — |
Total investments for deferred compensation plan |  | $ | 27,665 |  |  | $ | — |  |  | $ | — |  |  | $ | 28,431 |  |  | $ | — |  |  | $ | — |
Currency derivative assets included in other current assets |  | $ | — |  |  | $ | 668 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,517 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration included in accrued and other current liabilities |  | $ | — |  |  | $ | — |  |  | $ | 6,368 |  |  | $ | — |  |  | $ | — |  |  | $ | 8,042 |
Contingent consideration included in other non-current liabilities |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 3,971 |
Currency derivative liabilities included in accrued and other current liabilities |  | $ | — |  |  | $ | 3,519 |  |  | $ | — |  |  | $ | — |  |  | $ | 165 |  |  | $ | — |
Contingent Consideration for Business Acquisitions The following table summarizes the change in the fair value of the Company's contingent consideration balance during the nine months ended December 31, 2022 and 2021 (in thousands):
|  | Nine Months Ended December 31,
|  | 2022 |  | 2021
Beginning of the period |  | $ | 12,259 |  |  | $ | 6,967 |
Fair value of contingent consideration upon acquisition (1) |  | 2,151 |  |  | 9,973 |
Change in fair value of contingent consideration |  | — |  |  | (3,509) |
Settlement of contingent consideration |  | (5,954) |  |  | (880) |
Effect of foreign currency exchange rate changes |  | (1,843) |  |  | — |
End of the period |  | $ | 6,613 |  |  | $ | 12,551 |
(1) Represents the contingent consideration related to the technology acquisitions during the periods. The contingent consideration arising from the technology acquisition on May 19, 2021, represents the future potential earn-out payments of up to $10.0 million payable in cash only upon the achievement of three technical development milestones required to be completed as of December 31, 2021, June 30, 2022, and June 30, 2023. The fair value of the contingent consideration as of the acquisition date was $10.0 million, which was determined using a probability-weighted expected payment model and discounted at the estimated cost of debt. During the third quarter of fiscal year 2022, $0.9 million of the contingent consideration was released from other current liabilities upon cash settlement of the contingent consideration for the first technical development milestone. During the second quarter of fiscal year 2023, the Company paid $4.0 million for the contingent consideration related to the second technical development milestone. The contingent consideration arising from the Mevo Acquisition on February 17, 2021 represents the future potential earn-out payments of up to $17.0 million payable in cash only upon the achievement of certain net sales for the period from December 26, 2020 to December 31, 2021. As of March 31, 2021 the fair value of the contingent consideration was $3.4 million. A s of December 31, 2021, the fair value of the contingent consideration was released from other current liabilities as the net sales milestone was not achieved upon completion of the earn-out period. The contingent consideration arising from the technology acquisition on January 4, 2021, represents the future potential earn-out payments of up to $3.0 million payable in cash upon the achievement of two technical development milestones required to be completed as of December 31, 2021 and March 31, 2022. The fair value of the contingent amount was determined using a probability-weighted expected payment model and discounted at the estimated cost of debt. During the second quarter of fiscal year 2023, the Company paid $2.0 million for the contingent consideration related to the first technical development milestone. The Company expects to pay the remaining $1.0 million for the second technical development milestone within next twelve months. Although the estimate of contingent consideration is based on management’s best knowledge of current events, the estimate could change significantly from period to period. Actual results that differ from the assumptions used and any changes to the significant assumptions and unobservable inputs used could have an impact on future results of operations. Investment for Deferred Compensation Plan The marketable securities for the Company's deferred compensation plan were recorded at a fair value of $27.7 million and $28.4 million, as of December 31, 2022 and March 31, 2022, respectively, based on quoted market prices. Quoted market prices are observable inputs that are classified as Level 1 within the fair value hierarchy. Unrealized gains (losses) related to marketable securities for the three and nine months ended December 31, 2022 and 2021 were not material and were included in other income (expense), net in the Company's condensed consolidated statements of operations. Equity Method Investments The Company has certain non-marketable investments included in other assets that are accounted for as equity method investments, with a carrying value of $21.3 million and $40.2 million as of December 31, 2022 and March 31, 2022, respectively. Gains (losses) related to equity method investments for the three and nine months ended December 31, 2022 and 2021 were not material and are included in other income (expense), net in the Company's condensed consolidated statements of operations. During the nine months ended December 31, 2022, the Company recorded an impairment charge, before tax, of $21.4 million for one of its equity method investments as it was determined that the carrying value of the investment was not recoverable. The impairment charge is included in other income (expense), net in the Company's condensed consolidated statement of operations for the nine months ended December 31, 2022. There was no impairment of equity method investments during the three months ended December 31, 2022 and 2021 and the nine months ended December 31, 2021. Other Assets Measured at Fair Value on a Nonrecurring Basis Financial Assets. The Company has certain equity investments without readily determinable fair values due to the absence of quoted market prices, the inherent lack of liquidity, and the fact that inputs used to measure fair value are unobservable and require management's judgment. When certain events or circumstances indicate that impairment may exist, the Company revalues the investments using various assumptions, including the financial metrics and ratios of comparable public companies. The carrying value is also adjusted for observable price changes with the same or similar security from the same issuer. The amount of these equity investments without readily determinable fair value included in other assets was $10.9 million and $2.9 million as of December 31, 2022 and March 31, 2022, respectively. During the nine months ended December 31, 2022, the Company recorded an unrealized gain, before tax, of $6.9 million for its investment in a private company as a result of observable price changes for similar securities issued by this company (level 2 fair value measurement). There was no impairment of these financial assets during the three and nine months ended December 31, 2022 and 2021, other than an immaterial impairment charge related to one of the Company’s investments without readily determinable fair value recorded during the second quarter of fiscal year 2023. Non-Financial Assets. Goodwill, intangible assets, and property, plant and equipment, are not required to be measured at fair value on a recurring basis. However, if the Company is required to evaluate these non-financial assets for impairment, whether due to certain triggering events or because of the required annual impairment test, and a resulting impairment is recorded to reduce the carrying value to the fair value, the non-financial assets are measured at fair value during such period. There was no impairment of non-financial assets during the three and nine months ended December 31, 2022. During the three and nine months ended December 31, 2021, the Company recorded impairment charges of $7.0 million for the Jaybird-related intangible assets (see Note 8).

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration